A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...

Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

In a move that signals intensifying ambitions in the cancer therapeutics arena, pharmaceutical titan AbbVie Inc. unveiled Thursday a blockbuster $2 billion exclusive licensing agreement with Swiss ...

The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chro ...

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation of T cells. The growing prevalence of autoimmune ...

The study involves testing epcoritamab, administered subcutaneously, in combination with oral and intravenous anti-neoplastic agents. These include drugs like lenalidomide, ibrutinib, and polatuzumab ...

US pharma major Eli Lilly’s orforglipron is emerging as a promising oral glucagon-like peptide (GLP)-1 therapy, with upcoming clinical milestones in obesity and diabetes set to shape its market ...

At a lymphoma conference, experts sparred about treatment options, while an outside expert highlighted the value of each approach.

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...